Systematic review: andrographolide as a potential Anti-inflammatory treatment for psoriasis

Abstract

A chronic inflammatory skin condition called psoriasis affects 1-3% of people worldwide. It will lead to other psychological, endocrine, and cardiovascular issues. It mainly affects the elbows, knees, scalp, back, umbilicus, and lumbar regions and is distinguished by well-defined crimson plaques and thick silvery white scales. Topical corticosteroid cream has been the main therapy in treating inflammatory skin in psoriasis vulgaris until now. Nowadays, andrographolide is an active compound of Andrographis paniculate, or the name in Indonesia is Sambiloto, which has been reported as a potential anti-inflammatory. Therefore, this study aimed to systematically review the published efficacy of andrographolide as an anti-inflammatory in an in vivo study and synthesize the available data. This study was a literature review searched using PubMed/ Medline, Science Direct, and Cochrane up to September 2022. The following search terms were used: (andrographolide or Andrographis paniculate) AND (anti-inflammatory) AND (animal study or in vivo). The bias in the research using the Newcastle-Ottawa quality assessment score was rated as low risk, of some concern, or high risk. A total of six in vivo studies were included in our analysis. Methotrexate and biologic agents are used for the systemic treatment of psoriasis. Topical corticosteroid therapy remains the first line of topical therapy but has some side effects. Specific reporting of andrographolide as a potential anti-inflammatory in other inflammatory diseases is necessary to support the possible treatment for psoriasis. There still needs to be further studies regarding the use of andrographolide as a topical psoriasis treatment.